FGL2 and lymphoma: The FGL-2 activity in PBMC of this cohort of patients was similar to that observed in healthy controls (Mean ± SEM, 99%±27.9%; Median, 94%; p-value versus healthy controls  = 0.97, p-value versus lymphoma patients <0.001).